Close mobile menu×
Close mobile menu

Thomas Diacovo, MD

Board Certifications: 
Neonatal-Perinatal Medicine
Expertise in: 
Neonatology
Not Accepting New Patients
Treats Children
Profile Headshot

Schedule an Appointment

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Credentials & Experience

Board Certifications

  • Neonatal-Perinatal Medicine

Clinical Expertise

  • Pediatric Critical Care

Specialties

Education & Training

  • McGill University Faculty of Medicine
  • Residency: Baylor Affiliated Hospitals
  • Fellowship: Children's Hospital of Boston

About Thomas Diacovo

Academic Titles

  • Associate Professor of Pediatrics at CUMC

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center

Gender

  • Male

Research

Clinical Trials

NCT02564718 7-day Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Children From Birth to Less Than 6 Months With Arterial or Venous Thrombosis (Einstein Jr)

NCT02765633 A Prospective, Open-Label, Single-Arm, Single-Center Study To Assess The Pharmacokinetics/Pharmacodynamics (PK/PD) And Safety Of Different Cangrelor Doses In Neonatal Subjects At Risk Of Thrombosis

Grants

NEONATAL AND PEDIATRIC PLATELET FUNCTION AND PHARMACOLOGY (Federal Gov)

Jul 1 2015 - Jun 30 2020

NEONATAL AND PEDIATRIC PLATELET FUNCTION AND PHARMACOLOGY (Federal Gov)

Jul 1 2015 - Jun 30 2020

ANALYSIS OF PLATELET FUNCTION AND MICRORNA-MRNA PROFILES IN NEONATAL CARDIAC PATIENTS (Private)

Jul 1 2016 - Jun 30 2019

PRECLINICAL EVALUATION OF THE P2Y12 INHIBITOR CANGRELOR FOR USE IN PEDIATRIC PATIENTS (Private)

Jun 28 2013 - Jun 27 2018

ASSESSMENTOF BIOREACTOR-DERIVED HUMAN PLATELET QUALITY, STORAGE PROFILE, SAFETY, AND FUNCTION (Federal Gov)

Apr 1 2016 - Mar 31 2018

DEVELOPING A BIOLOGICALLY MATCHED TRANSFUSION PRODUCT FOR CRITICALLY ILL NEONATES: CORD BLOOD PLATELETS (Private)

Jul 1 2017 - Dec 31 2017

TARGETING NON-CLASSICAL ONCOGENES AS THERAPY FOR T-ALL (Federal Gov)

Aug 1 2012 - May 31 2017

TARGETING NON-CLASSICAL ONCOGENES AS THERAPY FOR T-ALL (Federal Gov)

Aug 1 2012 - May 31 2017

TARGETING NON-CLASSICAL ONCOGENES AS THERAPY FOR T-ALL (Federal Gov)

Aug 1 2012 - May 31 2017

PRECLINICAL AND CLINICAL EVALUATION OF PROTEIN KINASE INHIBITORS ON PLATELET FUNCTION (Private)

Sep 1 2014 - Aug 31 2015

GPIB ALPHA-VWF-A1 BOND KINETICS IN HEALTH AND DISEASE (Federal Gov)

Jul 1 2010 - Apr 30 2015

MULTISCALE MODEL OF PLATELET ADHESION AND THROMBUS FORMATION (Federal Gov)

Mar 8 2010 - Dec 31 2014

EVALUATING NEONATAL PLATELET FUNCTION AND RESPONSE TO ANTITHROMBOTIC AGENTS (Private)

Jul 1 2013 - Jun 30 2014

CLASS I PI3K INHIBITORS AS ADJUNCTIVE THERAPY FOR LEUKEMIA (Private)

Jul 1 2012 - Jun 30 2014

SPONSORED RESEARCH AGREEMENT WITH GILEAD (Private)

Jun 26 2012 - Jun 25 2014

TARGETING CLASS I PI3KS IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (Federal Gov)

Aug 1 2010 - Aug 31 2013

CLASS I P13KS AS A THERAPEUTIC TARGET IN ACUTE LYMPHOBLASTIC LEUKEMIA (Private)

Oct 1 2009 - Sep 30 2012

EPIC (R) IMAGING LABEL FREE DETECTION PROTOTYPE SYSTEM EVALU ATION AGREEMENT (Private)

Mar 17 2011 - Mar 16 2012

SPONSOREDRESEARCH AGREEMENT WITH CALISTOGA PHARMACEUTICALS, INC. (Private)

Mar 15 2011 - Mar 14 2012

A NOVEL ANIMAL MODEL FOR THROMBOTIC THROMBOCYTOPENIA PURPURA (TTP) (Private)

Jan 1 2010 - Dec 31 2011

A NOVEL BIOLOGICAL PLATFORM FOR DEVELOPMENT AND TESTING OF A NTITHROMBOTIC DRUGS AND TARGETED NON-INV (NY State Gov)

Mar 1 2008 - Oct 31 2011

P13KDELTA MODULATION OF NEUTROPHIL TRAFFICKING (Federal Gov)

Jul 1 2005 - Jul 31 2010

METHODS IN MOLECULAR IMAGING AND TARGETED THERAPEUTICS (Federal Gov)

Jul 1 2005 - Jun 30 2009

STRUCTURAL/FUNCTIONAL CHARACTERIZATION OF THE VWF-A1 DOMAIN (Federal Gov)

May 1 2000 - Apr 30 2009